ACE I/D、AGT M235T基因型与伊贝沙坦治疗高血压病降压疗效的关系研究

目的发现高血压患者与血管紧张素Ⅱ受体拮抗剂(伊贝沙坦)降压疗效相关的基因多态性位点。方法符合WHO/ISH高血压诊断标准的轻、中度高血压患者117例,服用伊贝沙坦单药治疗8周,在临床观察疗效的同时,用RFLP及PCR方法对患者血白细胞基因组DNA血管紧素-醛固酮系统基因多态性位点ACE I/D、AGT M235T基因型进行分析。结果含ACE D等位基因的患者服用伊贝沙坦后,收缩压下降幅度明显大于Ⅱ型基因型患者,两者之间有统计学差异(P<0.05);AGT M235T各基因型之间血压下降幅度均无显著差异。结论ACE I/D基因型与伊贝沙坦类药物的敏感性有一定相关性。

Relationship between gene polymorphisms of angiotensin converting enzyme insertion/deletion,angiotensinogen M235T and pressure-lowering response of irbesartan in the treatment hypertension patients

Objective To determine whether polymorphisms in the renin-angiotensin system can predict blood pressure-lowing response to angiotensin n receptor type 1 antagonist treatment, specifically, in response to treatment with irbesartan. Methods One hunderd seventeen patients with mild to moderate essential hypertension diagnosted according to the criteria of hypertension of WHO/ISH were enrolled in and treated with irbesartan for 8 weeks. Gene polymorphisms: angiotensin converting enzyme insertion/deletion (ACE I/D), angiotensinogen M235T(AGT M235T) were detected the relation between genotypes and blood pressure reduction wes analysed. Results Individuals with the ACE gene D allele showed a greater reduction in systolic blood pressure than those homozygous for I allele (16.65 ?12.81 versus 11.98 ?10.17 mmHg, P>0.05). The angiotensinogen M235T was not related to the response to treatment. Conclusion ACE genotyping was related with the blood pressure-lowering response to antihypertensive treatment with irbesartan.